Preclinical Characterization of the Novel Hepatitis C Virus NS3 Protease Inhibitor GS-9451

Discovery of the First C-Nucleoside HCV Polymerase Inhibitor (GS-6620) with Demonstrated Antiviral Response in HCV Infected Patients

(2013) Aesop Cho et al.   JOURNAL OF MEDICINAL CHEMISTRY

Discovery of Ledipasvir (GS-5885): A Potent, Once-Daily Oral NS5A Inhibitor for the Treatment of Hepatitis C Virus Infection

(2013) John O. Link et al.   JOURNAL OF MEDICINAL CHEMISTRY

Preclinical Characterization of GS-9669, a Thumb Site II Inhibitor of the Hepatitis C Virus NS5B Polymerase

(2012) M. Fenaux et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Characterization of Resistance to the Protease Inhibitor GS-9451 in Hepatitis C Virus-Infected Patients

(2012) Hadas Dvory-Sobol et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A Phase 1, randomized, placebo-controlled, three-day, ascending-dose study of GS-9451, an NS3/4A protease inhibitor, in genotype 1 hepatitis C patients

(2012) Eric J Lawitz et al.   ANTIVIRAL THERAPY

Discovery of GS-9451: An acid inhibitor of the hepatitis C virus NS3/4A protease

(2012) X. Christopher Sheng et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Mechanistic Characterization of GS-9190 (Tegobuvir), a Novel Nonnucleoside Inhibitor of Hepatitis C Virus NS5B Polymerase

(2011) I-hung Shih et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Selection of Clinically Relevant Protease Inhibitor-Resistant Viruses Using the Genotype 2a Hepatitis C Virus Infection System

(2011) Guofeng Cheng et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in Humans: In Vitro and In Vivo Correlations

(2011) Robert A. Fridell et al.   HEPATOLOGY

Novel Mutations in a Tissue Culture-Adapted Hepatitis C Virus Strain Improve Infectious-Virus Stability and Markedly Enhance Infection Kinetics

(2011) M. V. Pokrovskii et al.   JOURNAL OF VIROLOGY

Boceprevir for Untreated Chronic HCV Genotype 1 Infection

(2011) Fred Poordad et al.   NEW ENGLAND JOURNAL OF MEDICINE

Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection

(2011) Bruce R. Bacon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection

(2011) Ira M. Jacobson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Preexisting drug-resistance mutations reveal unique barriers to resistance for distinct antivirals

(2011) M. Robinson et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Novel Hepatitis C Virus Reporter Replicon Cell Lines Enable Efficient Antiviral Screening against Genotype 1a

(2010) M. Robinson et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

(2010) Paul Y Kwo et al.   LANCET

Telaprevir for Previously Treated Chronic HCV Infection

(2010) John G. McHutchison et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparison of HCV NS3 protease and NS5B polymerase inhibitor activity in 1a, 1b and 2a replicons and 2a infectious virus

(2009) Matthew S. Paulson et al.   ANTIVIRAL RESEARCH

Resistance to Direct Antiviral Agents in Patients With Hepatitis C Virus Infection

(2009) Christoph Sarrazin et al.   GASTROENTEROLOGY

Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection

(2009) Christophe Hézode et al.   NEW ENGLAND JOURNAL OF MEDICINE

Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection

(2009) John G. McHutchison et al.   NEW ENGLAND JOURNAL OF MEDICINE

Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection

(2009) John G. McHutchison et al.   NEW ENGLAND JOURNAL OF MEDICINE

Development of a replicon-based phenotypic assay for assessing the drug susceptibilities of HCV NS3 protease genes from clinical isolates

(2008) Xiaoping Qi et al.   ANTIVIRAL RESEARCH